List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6946256/publications.pdf Version: 2024-02-01



Δμιτ Μ Οζλ

#	Article	IF	CITATIONS
1	Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. New England Journal of Medicine, 2016, 375, 2154-2164.	27.0	1,860
2	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. New England Journal of Medicine, 2018, 379, 2495-2505.	27.0	1,854
3	A Phase 3 Trial of Bevacizumab in Ovarian Cancer. New England Journal of Medicine, 2011, 365, 2484-2496.	27.0	1,843
4	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1274-1284.	10.7	1,376
5	Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet, The, 2014, 383, 1721-1730.	13.7	1,361
6	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1949-1961.	13.7	1,261
7	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
8	Epithelial ovarian cancer. Lancet, The, 2019, 393, 1240-1253.	13.7	1,039
9	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncology, The, 2011, 12, 852-861.	10.7	1,028
10	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 75-87.	10.7	975
11	Epithelial ovarian cancer: Evolution of management in the era of precision medicine. Ca-A Cancer Journal for Clinicians, 2019, 69, 280-304.	329.8	821
12	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncology, The, 2015, 16, 928-936.	10.7	661
13	Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial. Journal of Clinical Oncology, 2003, 21, 2059-2069.	1.6	613
14	Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. Journal of Clinical Oncology, 2008, 26, 76-82.	1.6	511
15	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 87-97.	10.7	491
16	Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2019, 20, 636-648.	10.7	366
17	Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. Journal of Clinical Oncology, 2011, 29, 3278-3285.	1.6	321
18	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2017, 7, 984-998.	9.4	310

AMIT M OZA

#	Article	IF	CITATIONS
19	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2014, 15, 799-808.	10.7	279
20	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discovery, 2019, 9, 210-219.	9.4	278
21	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology, 2017, 147, 267-275.	1.4	222
22	A Phase l–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <i>BRCA1/2</i> -Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research, 2017, 23, 4095-4106.	7.0	213
23	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. Genome Medicine, 2016, 8, 109.	8.2	211
24	Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2016, 34, 4371-4380.	1.6	203
25	Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian Cancer. Journal of Clinical Oncology, 2001, 19, 1266-1274.	1.6	175
26	Outcomes and endpoints in trials of cancer treatment: the past, present, and future. Lancet Oncology, The, 2015, 16, e32-e42.	10.7	152
27	Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. Journal of Clinical Oncology, 2008, 26, 4319-4325.	1.6	137
28	Treatment strategies for endometrial cancer: current practice and perspective. Current Opinion in Obstetrics and Gynecology, 2017, 29, 47-58.	2.0	133
29	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research, 2013, 19, 5485-5493.	7.0	126
30	Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncology, The, 2013, 14, 236-243.	10.7	125
31	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, The, 2021, 397, 281-292.	13.7	125
32	Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or <i>BRCA</i> -Mutant Ovarian Cancer. Clinical Cancer Research, 2015, 21, 1574-1582.	7.0	124
33	Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. Cancer, 2007, 109, 692-702.	4.1	122
34	Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma. JAMA Oncology, 2018, 4, e173776.	7.1	116
35	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature Communications, 2021, 12, 2487.	12.8	116
36	Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer, 2014, 120, 3932-3939.	4.1	114

#	Article	IF	CITATIONS
37	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clinical Cancer Research, 2017, 23, 4086-4094.	7.0	114
38	Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer. Cancers, 2020, 12, 1607.	3.7	104
39	Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma. Journal of Clinical Oncology, 2015, 33, 3576-3582.	1.6	97
40	Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncology, The, 2018, 19, 1117-1125.	10.7	95
41	A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: A trial of the Chicago, PMH, and California Phase II Consortia. Gynecologic Oncology, 2010, 117, 37-40.	1.4	92
42	Gynecologic Cancer InterGroup (GCIG) Consensus Review for Mucinous Ovarian Carcinoma. International Journal of Gynecological Cancer, 2014, 24, S14-S19.	2.5	87
43	ls the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology, 2017, 145, 584-594.	1.4	85
44	Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology, 2014, 135, 184-189.	1.4	84
45	EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression. Clinical Cancer Research, 2020, 26, 4206-4215.	7.0	84
46	Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecologic Oncology, 2016, 143, 27-34.	1.4	81
47	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecologic Oncology, 2013, 130, 25-30.	1.4	79
48	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncolmmunology, 2015, 4, e1026529.	4.6	79
49	Somatic <i>BRCA1/2</i> Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. Journal of Clinical Oncology, 2017, 35, 1240-1249.	1.6	79
50	Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: Results from studies of the NCIC Clinical Trials Group (NCIC CTG). European Journal of Cancer, 2010, 46, 1365-1373.	2.8	75
51	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation Journal of Clinical Oncology, 2020, 38, 6002-6002.	1.6	75
52	Outcomes and endpoints in cancer trials: bridging the divide. Lancet Oncology, The, 2015, 16, e43-e52.	10.7	72
53	Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors. Genome Medicine, 2018, 10, 81.	8.2	72
54	A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology, 2016, 142, 62-69.	1.4	70

#	Article	IF	CITATIONS
55	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. European Journal of Cancer, 2017, 70, 111-121.	2.8	70
56	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 710-722.	10.7	70
57	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 465-478.	10.7	70
58	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2019, 20, 862-876.	10.7	68
59	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i> -mutant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 4767-4776.	7.0	68
60	A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology, 2015, 137, 216-222.	1.4	65
61	Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer, 2014, 120, 603-610.	4.1	64
62	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. Journal of Clinical Oncology, 2020, 38, 3528-3537.	1.6	64
63	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer. Clinical Cancer Research, 2014, 20, 4549-4558.	7.0	63
64	A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecologic Oncology, 2015, 138, 55-61.	1.4	62
65	Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study. International Journal of Gynecological Cancer, 2017, 27, 50-58.	2.5	61
66	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis Journal of Clinical Oncology, 2015, 33, 5508-5508.	1.6	60
67	Intermediate clinical endpoints: A bridge between progressionâ€free survival and overall survival in ovarian cancer trials. Cancer, 2015, 121, 1737-1746.	4.1	59
68	A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecologic Oncology, 2014, 134, 274-280.	1.4	58
69	Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer. Investigational New Drugs, 2016, 34, 355-363.	2.6	58
70	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncology, 2018, 14, 1669-1678.	2.4	55
71	Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. International Journal of Gynecological Cancer, 2020, 30, 903-915.	2.5	52
72	A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 1182-1191.	2.6	50

#	Article	IF	CITATIONS
73	Intravenous aflibercept in patients with platinumâ€resistant, advanced ovarian cancer: Results of a randomized, doubleâ€blind, phase 2, parallelâ€arm study. Cancer, 2014, 120, 335-343.	4.1	49
74	Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 Mutations. Cancers, 2019, 11, 416.	3.7	49
75	Stage I granulosa cell tumours: A management conundrum? Results of long-term follow up. Gynecologic Oncology, 2015, 138, 285-291.	1.4	47
76	The World Ovarian Cancer Coalition Every Woman Study: identifying challenges and opportunities to improve survival and quality of life. International Journal of Gynecological Cancer, 2021, 31, 238-244.	2.5	47
77	A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clinical Cancer Research, 2018, 24, 6168-6174.	7.0	44
78	Endometrial cancer—targeted therapies myth or reality? Review of current targeted treatments. European Journal of Cancer, 2016, 59, 99-108.	2.8	40
79	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. Gynecologic Oncology, 2019, 152, 53-60.	1.4	40
80	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 632-642.	10.7	40
81	ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1589-1594.	2.5	40
82	ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. European Journal of Cancer, 2013, 49, 121-131.	2.8	38
83	Better Therapeutic Trials in Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, dju029-dju029.	6.3	36
84	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
85	Niraparib for the treatment of ovarian cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 631-640.	1.8	35
86	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: Data from CALYPSO trial (a GINECO-GCIG study). Gynecologic Oncology, 2013, 130, 289-294.	1.4	34
87	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. Clinical Lung Cancer, 2014, 15, 52-57.	2.6	32
88	Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. Clinical Cancer Research, 2022, 28, 36-44.	7.0	32
89	Ovarian cancer treatment: The end of empiricism?. Cancer, 2015, 121, 3203-3211.	4.1	30
90	<i>TP53</i> mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses. International Journal of Gynecological Cancer, 2019, 29, 346-352.	2.5	29

#	Article	IF	CITATIONS
91	A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve. Oncologist, 2018, 23, 203-213.	3.7	28
92	High <i>EMSY</i> expression defines a BRCAâ€like subgroup of highâ€grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum. Cancer, 2019, 125, 2772-2781.	4.1	28
93	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. Journal of Clinical Oncology, 2020, 38, 3494-3505.	1.6	28
94	Advances in ovarian cancer, from biology to treatment. Nature Cancer, 2021, 2, 6-8.	13.2	26
95	Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 111-117.	0.8	25
96	Malignant Bowel Obstruction in Advanced Gynecologic Cancers: An Updated Review from a Multidisciplinary Perspective. Obstetrics and Gynecology International, 2018, 2018, 1-10.	1.3	23
97	COVID-19 Testing in Patients with Cancer: Does One Size Fit All?. Clinical Cancer Research, 2020, 26, 4737-4742.	7.0	23
98	Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. Gynecologic Oncology, 2018, 149, 275-282.	1.4	22
99	Dynamic modeling in ovarian cancer: An original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecologic Oncology, 2014, 133, 460-466.	1.4	21
100	Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study. Oncologist, 2017, 22, 1117-1124.	3.7	20
101	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. Gynecologic Oncology, 2021, 163, 490-497.	1.4	20
102	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i> -mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer, 2019, 29, 1396-1404.	2.5	19
103	QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens Journal of Clinical Oncology, 2018, 36, 5514-5514.	1.6	19
104	A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. Journal of Translational Medicine, 2016, 14, 83.	4.4	18
105	Updates and current challenges in microRNA research for personalized medicine in ovarian cancer. Expert Opinion on Biological Therapy, 2017, 17, 927-943.	3.1	18
106	Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of Disease Progression to Overcome Treatment Failure: A Trial of the Princess Margaret Phase II Consortium. Blood, 2016, 128, 4526-4526.	1.4	17
107	Additional germline findings from a tumor profiling program. BMC Medical Genomics, 2018, 11, 65.	1.5	16
108	Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer. Journal of Oncology Practice, 2019, 15, e1066-e1075.	2.5	16

#	Article	IF	CITATIONS
109	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical Cancer Research, 2020, 26, 2477-2486.	7.0	16
110	Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention. Frontiers in Oncology, 2016, 6, 119.	2.8	15
111	Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer. Cancer, 2020, 126, 4886-4894.	4.1	15
112	Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in <i>Akt1</i> E17K mutation positive advanced solid tumors. Molecular Cancer Therapeutics, 2015, 14, B109-B109.	4.1	15
113	A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia Journal of Clinical Oncology, 2019, 37, 5518-5518.	1.6	15
114	Safety evaluation of olaparib for treating ovarian cancer. Expert Opinion on Drug Safety, 2015, 14, 1305-1316.	2.4	14
115	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. Gynecologic Oncology, 2020, 159, 101-111.	1.4	14
116	Recent advances in systemic therapy for advanced endometrial cancer. Current Opinion in Oncology, 2011, 23, 494-500.	2.4	13
117	Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?. Cancers, 2020, 12, 3296.	3.7	13
118	Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e152-e166.	3.8	12
119	A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors. Oncologist, 2021, 26, e2254-e2264.	3.7	12
120	Aspirin in Prevention of Ovarian Cancer: Are We at the Tipping Point?. Journal of the National Cancer Institute, 2014, 106, djt453-djt453.	6.3	11
121	Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions. Gynecologic Oncology, 2016, 140, 90-94.	1.4	11
122	Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials. Expert Opinion on Orphan Drugs, 2017, 5, 71-83.	0.8	11
123	Targeting Angiogenesis. Hematology/Oncology Clinics of North America, 2018, 32, 1041-1055.	2.2	11
124	Olaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs, 2014, 2, 497-508.	0.8	10
125	The role of niraparib for the treatment of ovarian cancer. Future Oncology, 2018, 14, 2565-2577.	2.4	10
126	Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer Journal of Clinical Oncology, 2012, 30, 5025-5025.	1.6	10

#	Article	IF	CITATIONS
127	Performance characteristics of a brief Family History Questionnaire to screen for Lynch syndrome in women with newly diagnosed endometrial cancer. Gynecologic Oncology, 2015, 136, 311-316.	1.4	9
128	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e247-e257.	3.8	9
129	New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?. Current Oncology Reports, 2016, 18, 23.	4.0	9
130	Supported self-management as a model for end-of-life care in the setting of malignant bowel obstruction: A qualitative study. Gynecologic Oncology, 2020, 157, 745-753.	1.4	9
131	Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study. Gynecologic Oncology, 2021, 161, 221-227.	1.4	9
132	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. European Journal of Cancer, 2021, 154, 190-200.	2.8	9
133	Clinical data from the DeCidE ¹ trial: Assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer Journal of Clinical Oncology, 2018, 36, 5510-5510.	1.6	9
134	Current and emerging treatment options in the management of advanced ovarian cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1063-1076.	1.8	8
135	Heterogeneous alteration of the ERBB3–MYC axis associated with MEK inhibitor resistance in a <i>KRAS</i> -mutated low-grade serous ovarian cancer patient. Journal of Physical Education and Sports Management, 2019, 5, a004341.	1.2	8
136	Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?. Clinical Cancer Research, 2020, 26, 523-525.	7.0	8
137	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e247-e257.	3.8	8
138	A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Investigational New Drugs, 2016, 34, 231-235.	2.6	7
139	Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients. Gynecologic Oncology, 2019, 153, 304-311.	1.4	7
140	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. International Journal of Gynecological Cancer, 2021, 31, 949-958.	2.5	7
141	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. Gynecologic Oncology, 2021, 161, 668-675.	1.4	7
142	Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts Journal of Clinical Oncology, 2017, 35, 5547-5547.	1.6	7
143	Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention. Gynecologic Oncology, 2015, 138, 235-237.	1.4	6
144	Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study. Radiotherapy and Oncology, 2017, 124, 74-79.	0.6	6

#	Article	IF	CITATIONS
145	Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions. Cells, 2019, 8, 200.	4.1	6
146	DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. International Journal of Gynecological Cancer, 2020, 30, 1824-1828.	2.5	6
147	Across barriers: poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases. International Journal of Gynecological Cancer, 2021, 31, 139-143.	2.5	6
148	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer Journal of Clinical Oncology, 2021, 39, TPS5610-TPS5610.	1.6	6
149	Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer. Cancer, 2021, 127, 3082-3091.	4.1	6
150	Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging Disease. Journal of Clinical Oncology, 2021, 39, 1513-1517.	1.6	6
151	Ethical frameworks in clinical research processes during COVID-19: a scoping review. BMJ Open, 2021, 11, e047076.	1.9	6
152	Efficacy and safety of olaparib according to age in BRCA-1/2 mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2 (AGO-OVAR 2.23/ENGOT-Ov21) study Journal of Clinical Oncology, 2020, 38, 6068-6068.	1.6	6
153	Advances in prediction for ovarian cancer treatment stratification. Nature Reviews Clinical Oncology, 2019, 16, 75-76.	27.6	5
154	Optimizing clinical research procedures in public health emergencies. Medicinal Research Reviews, 2021, 41, 725-738.	10.5	5
155	Moving From Mutation to Actionability. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 495-503.	3.8	4
156	Targeting TGFβ Pathway in Adult Granulosa Cell Tumor: Opening Pandora's Box?. Clinical Cancer Research, 2019, 25, 5432-5434.	7.0	4
157	Outcome according to residual disease (surgeon's report vs preâ€chemotherapy imaging) in patients with bevacizumabâ€treated ovarian cancer: Analysis of the ROSiA study. Journal of Surgical Oncology, 2019, 120, 786-793.	1.7	4
158	Conservative management of adnexal masses. Lancet Oncology, The, 2019, 20, 326-327.	10.7	4
159	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. Gynecologic Oncology, 2020, 159, 539-545.	1.4	4
160	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. Modern Pathology, 2020, 33, 2361-2377.	5.5	4
161	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinumâ€based regimen and disease at baseline on efficacy and safety. Cancer Medicine, 2021, 10, 7162-7173.	2.8	4
162	Repurposing Itraconazole and Hydroxychloroquine to Target Lysosomal Homeostasis in Epithelial Ovarian Cancer. Cancer Research Communications, 2022, 2, 293-306.	1.7	4

#	Article	IF	CITATIONS
163	Estimation of expectedness: Predictive accuracy of standard therapy outcomes in randomized phase 3 studies in epithelial ovarian cancer. Cancer, 2015, 121, 413-422.	4.1	3
164	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 994-1002.	0.8	3
165	Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature. Current Oncology, 2021, 28, 661-670.	2.2	3
166	Research biopsies in patients with gynecologic cancers: patient-reported outcomes, perceptions, and preferences. American Journal of Obstetrics and Gynecology, 2021, 225, 658.e1-658.e9.	1.3	3
167	The Prevent Ovarian Cancer Program (POCP): Identification of women at risk for ovarian cancer using complementary recruitment approaches. Gynecologic Oncology, 2021, 162, 97-106.	1.4	3
168	Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC) Journal of Clinical Oncology, 2013, 31, 5518-5518.	1.6	3
169	Feasibility and safety of front-line bevacizumab (BEV)-containing therapy after neoadjuvant (NA) chemotherapy (CT) for ovarian cancer (OC): The ROSiA experience Journal of Clinical Oncology, 2013, 31, 5541-5541.	1.6	3
170	Targeting the microenvironment in ovarian cancer. Lancet Oncology, The, 2015, 16, 485-486.	10.7	2
171	Emerging growth factor receptor antagonists for ovarian cancer treatment. Expert Opinion on Emerging Drugs, 2018, 23, 1-16.	2.4	2
172	Measurement Tool of Chemotherapy Sensitivity in Advanced Ovarian Cancer. Clinical Cancer Research, 2020, 26, 4432-4434.	7.0	2
173	Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer Journal of Clinical Oncology, 2015, 33, 3072-3072.	1.6	2
174	Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study Journal of Clinical Oncology, 2016, 34, 5535-5535.	1.6	2
175	Prospective evaluation of quality of life (QOL) during a phase I/II study of adjuvant chemotherapy with image-guided high-precision radiotherapy for completely resected gastric cancer Journal of Clinical Oncology, 2016, 34, 164-164.	1.6	2
176	Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial Journal of Clinical Oncology, 2017, 35, 5581-5581.	1.6	2
177	Non-target progression – The fine line between objectivity and subjectivity. European Journal of Cancer, 2014, 50, 3271-3272.	2.8	1
178	Discrepancies in drug approvals: A global dilemma. Cancer, 2015, 121, 3360-3361.	4.1	1
179	Resisting RECIST—Uniformity Versus Clinical Validity. International Journal of Gynecological Cancer, 2017, 27, 1619-1627.	2.5	1
180	Efficacy and safety updates of poly ADP-ribose polymerase (PARP) inhibitor maintenance in ovarian cancer from ASCO 2020. International Journal of Gynecological Cancer, 2020, 30, 1256-1257.	2.5	1

#	Article	IF	CITATIONS
181	Moving Beyond BRCA—Incorporating Molecular Assays into Ovarian Cancer Trials. Clinical Cancer Research, 2020, 26, 5271-5273.	7.0	1
182	Impact of an internal medicine nocturnist service on care of patients with cancer at a large Canadian teaching hospital: a quality-improvement study. CMAJ Open, 2021, 9, E667-E672.	2.4	1
183	Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series. Gynecologic Oncology Reports, 2021, 36, 100729.	0.6	1
184	Targeted Therapy in Management of Endometrial Cancer. , 2020, , 249-276.		1
185	With Our Powers Combined. Cancer Journal (Sudbury, Mass), 2021, 27, 511-520.	2.0	1
186	Updates on systemic therapy for cervical cancer. Indian Journal of Medical Research, 2021, 154, 293.	1.0	1
187	Double trouble: whole genome doubling distinguishes early from late ovarian cancer. Clinical Cancer Research, 2022, , .	7.0	1
188	A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers. Current Oncology, 2022, 29, 4354-4369.	2.2	1
189	PEGylated liposomal doxorubicin: present and future role in the treatment of ovarian cancer. Expert Review of Obstetrics and Gynecology, 2008, 3, 21-31.	0.4	0
190	The role of cediranib in ovarian cancer: current status and further investigation. Expert Opinion on Orphan Drugs, 2016, 4, 855-865.	0.8	0
191	DNA Repair Defects for Therapy in Ovarian Cancer: The BRCA1/2 and PARP Inhibitor Story. Indian Journal of Gynecologic Oncology, 2017, 15, 65-75.	0.3	0
192	Rucaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs, 2018, 6, 151-161.	0.8	0
193	Adjuvant treatment in early stage cervical cancer—does more equal better?. International Journal of Gynecological Cancer, 2020, 30, 1467-1468.	2.5	0
194	Quality assurance metrics in clinical trial conduct Journal of Clinical Oncology, 2016, 34, 274-274.	1.6	0
195	Prognostic effects of clinical and tumor (t) factors in bevacizumab (BEV)-treated patients (pts) with ovarian cancer (OC) Journal of Clinical Oncology, 2016, 34, 5556-5556.	1.6	0
196	Brief family history questionnaire to screen for Lynch syndrome in women with newly diagnosed non-serous, non-mucinous ovarian cancers. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003082.	2.5	0
197	Efficacy and safety of rucaparib maintenance treatment in patients from ARIEL3 with platinum-sensitive, recurrent ovarian carcinoma not associated with homologous recombination deficiency Journal of Clinical Oncology, 2022, 40, 5544-5544.	1.6	0